Commenters debated the wider use of GLP‑1 drugs, with some warning of overuse and side effects and others arguing they meet real needs. faangguyindia warned that widespread appetite suppression could increase gallbladder and bile problems, said most people don’t need GLP‑1s if they understand calorie deficit, and promoted a free tool (Macrocodex) to manage intake. Several others countered that maintaining a calorie deficit is very hard for the average person (Zironic, toomuchtodo cited a Lancet Psychiatry link), and that GLP‑1s make sustained intake reduction feasible. Concerns about crash dieting, hair loss, and misuse were raised alongside claims that many diets and studies set people up to fail.
Opinion also split on culpability and evidence. multifasciatus highlighted potential residual confounding and selection bias in the study and urged randomized trials to confirm benefits; toomuchtodo and others echoed the call for more rigorous research. redanddead blamed the processed food industry for creating obesogenic environments and said GLP‑1s are a market “failure mode,” while also noting they can be lifesaving in high‑risk populations such as diabetics in South Asia. The debate centers on whether drugs are an appropriate corrective for behavioral and environmental problems or a risky shortcut that needs stronger clinical proof.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.